Complex science, translated into
strategic impact.
Griffentis helps biotech and pharma innovators build medical affairs strategy, sharpen the scientific narrative, and guide the clinical development decisions that shape a program's trajectory.
Griffentis works where science, strategy, and execution meet, helping biotech and pharma leaders make complex science clear, credible, and strategically actionable.
Senior-led support across medical affairs and communications
From medical strategy to the scientific story that carries a program, Griffentis brings integrated scientific and strategic judgment to the decisions that matter most to innovators.
Medical Affairs Strategy and Build
Pre-launch and launch readiness, lifecycle planning, and the design and optimization of medical affairs functions, including field medical, medical information, medical education, and publications.
Scientific Narrative and Publications
Scientific narrative development, publication and congress strategy, data-disclosure planning, and the medical writing to execute it. Clear, balanced, evidence-based materials, tailored to each audience.
Development and External Innovation Strategy
Translational rationale, study-design perspective, the partnering narrative, non-dilutive funding strategy, and diligence support. For programs deciding where to go next and how to fund it.
Concrete ways clients work with Griffentis
Engagements are scoped to the decision in front of you, from a single document or focused review to an ongoing advisory relationship.
- Medical writing and scientific document development
- Scientific platform development
- Medical affairs launch-readiness review
- KOL mapping and advisory board strategy
- Publication and data-disclosure strategy
- Clinical and translational strategy input
- Partnering narrative and diligence support
From complex science to a story that moves decisions
Every engagement follows the same discipline: understand the science deeply, then shape it into strategy and communication that are clear, accurate, and fit for the audience.
Understand the science
We start with the data and the mechanism, separating hypothesis from evidence and preclinical signal from clinical relevance before any narrative is built.
Define the strategy
We translate that understanding into a medical, communications, or partnering strategy aligned with where the program needs to go and the decisions ahead.
Shape the narrative
We craft the scientific story and supporting materials so that complex science is clear and accurate for each audience.
Engage the stakeholders
We build the KOL, advisory, and stakeholder plans that carry the science into the field, grounded in legitimate scientific exchange.
Science, strategy, and communication in one place
Most teams have to assemble these capabilities from separate advisors. Griffentis brings them together in a single senior-led practice.
Real scientific depth
Grounded in molecular biology, translational science, and clinical development, so the strategy and the story hold up to expert scrutiny, not just a polished surface.
Decision-ready judgment
An integrated lens that weighs scientific, clinical, regulatory, and commercial considerations together, with trade-offs and risks made explicit.
Clarity without overstatement
The ability to make complex science clear and accurate for boards, investors, partners, and peers, without oversimplifying the data or omitting its limitations.
Senior support without building a large internal function
Griffentis works with small and mid-sized biotech and pharma teams that need senior scientific, medical affairs, and strategic communications support.
Typical clients include founder-led biotech companies, clinical-stage teams, medical affairs and scientific communications leaders, product and development teams, and organizations preparing for financing, partnering, lifecycle, or stakeholder engagement decisions.
The Myth of Ritae Griffenticas
Legend says the Ritae Griffenticas is ancestor to the tiny guardians once kept beside kings: small in stature, sharp in judgment, and impossible to distract from what mattered.
Perched above the valley, she watched over winding paths, hidden risks, and decisions that could shape entire kingdoms. With a narrowed eye and silver crest, she saw the pattern others missed and guided travelers toward the clearest path.
Today, her spirit lives on at Griffentis: bringing clarity, strategy, and perspective to complexity across biotech, medical affairs, and medical communications.
Built on deep life sciences experience
Griffentis was founded by Mirta Grifman, PhD, a senior biotech and pharma leader with 25 years of industry experience spanning molecular biology, translational science, medical affairs, clinical development, external innovation, and business development.
Dr. Grifman has built medical affairs functions, shaped scientific narratives from discovery through launch, and supported partnering and licensing decisions. Griffentis brings that operator perspective to founders and executives navigating high-stakes scientific and strategic decisions.
The name draws on the griffin, a guardian that pairs vision with strength, as a quiet emblem of science guided by judgment.
Talk through the science in front of you
Whether you need a medical strategy shaped, a scientific narrative built, or the documents themselves written, Griffentis can help you think it through and deliver the finished work.
Please do not send confidential, proprietary, clinical, patient, or regulated information until an appropriate confidentiality agreement is in place.